Health authorities and researchers are tracking a newly notable Omicron-lineage SARS-CoV-2 variant known as BA.3.2, nicknamed “cicada.” First identified in South Africa in November 2024, it reappeared in the United States after a months-long lull and has been detected across multiple countries. Laboratory studies show it carries roughly 70–75 mutations relative to the currently dominant strains, raising questions about immune escape even as clinical evidence on severity and spread remains limited. Public health officials are monitoring trends after the variant was found in wastewater and patient samples in several regions.
Key Takeaways
- BA.3.2, called “cicada,” was first reported in South Africa in November 2024 and resurfaced internationally later; one U.S. traveler sample was identified in June 2025.
- As of Feb. 11, the U.S. Centers for Disease Control and Prevention reported detections of this lineage in 25 states, though it remains a minority strain nationally.
- In parts of Northern Europe this winter, BA.3.2 accounted for about 30% of sequenced cases in Germany, Denmark and the Netherlands.
- The variant carries approximately 70–75 mutations compared with dominant strains, a profile that laboratory assays suggest could reduce neutralization by vaccine- or infection-derived antibodies.
- Clinical data are sparse; infectious-disease specialists say there is currently no clear signal that BA.3.2 causes more severe illness than recent variants.
- Public-health surveillance methods detecting BA.3.2 include wastewater monitoring, traveler nasal-swab programs and sequencing of clinical samples from hospitals and outpatient settings.
- Home antigen tests remain designed to detect conserved viral regions and are expected to identify infections with this lineage, provided kits are used before expiration.
Background
Since the emergence of Omicron in late 2021, SARS-CoV-2 has continued to evolve with multiple sublineages rising and falling in prevalence. Health agencies and researchers use international genomic sequencing networks to identify novel lineages, then track their spread through clinical sequencing, traveler surveillance and wastewater sampling. The BA.3.2 lineage was noted in genomic databases in late 2024 and then appeared intermittently before registering renewed detections across Europe and North America.
Viral evolution occasionally produces sublineages with many spike-protein changes; some of these alterations affect antibody binding while others have little practical effect on transmission or disease. Public-health bodies incorporate those genetic data into laboratory neutralization studies and epidemiological surveillance to estimate vaccine effectiveness and population risk. Because BA.3.2 has a relatively large constellation of mutations, it has prompted heightened attention even though population-level impact is not yet established.
Main Event
Genomic surveillance flagged BA.3.2 in South Africa in November 2024, and a later single detection in a U.S. traveler was reported in June 2025. Broader U.S. detections were recorded in late December and early January, with the CDC noting presence across 25 states by Feb. 11. In Europe, the variant increased in share during winter months, reaching roughly 30% of sequenced infections in three Northern European countries.
Laboratory teams quickly ran neutralization assays comparing BA.3.2 to circulating strains. Those in vitro tests indicated reduced antibody neutralization from sera of people vaccinated or previously infected with recent variants, suggesting partial immune escape. Experts emphasize that lab-neutralization results do not directly equate to clinical vaccine failure, but they are an early signal that may prompt vaccine composition reviews.
Clinicians have not reported a distinct clinical syndrome associated with BA.3.2; hospitalization and severity indications remain similar to what has been observed with recent Omicron sublineages. Public-health officials continue to combine sequencing results with case, hospitalization and wastewater data to determine whether BA.3.2 is displacing other variants or staying at low prevalence.
Analysis & Implications
BA.3.2’s mutation load—approximately 70–75 differences compared with dominant strains—makes it genetically notable, but mutations alone do not determine public-health impact. What matters more is a combination of transmissibility, immune evasion, and the variant’s ability to cause severe disease. Early laboratory evidence of reduced neutralization raises the prospect that BA.3.2 could infect people with prior immunity more readily than current strains, which may translate into increased case counts if the variant achieves a transmission advantage.
However, multiple experts caution that many variants with concerning genetics have not become dominant in a population. Real-world spread depends on factors such as existing population immunity, coincident respiratory-season dynamics, and stochastic chance events. In countries where BA.3.2 rose to higher proportions this winter, its trajectory will inform but not predict what happens elsewhere because travel patterns and immunity landscapes differ.
For vaccination policy, the immediate implication is monitoring rather than a panicked change. The current vaccine formula remains in place through fall 2026 and continues to offer protection—particularly against severe outcomes—even when neutralization titers are lowered. Manufacturers and advisory groups will weigh BA.3.2 data alongside other circulating lineages when selecting strains for future vaccine updates.
Comparison & Data
| Metric | BA.3.2 (cicada) | Typical recent Omicron sublineages |
|---|---|---|
| First identified | Nov 2024 (South Africa) | Varies (2021–2024) |
| Mutations vs dominant strains | ~70–75 | Fewer (varies) |
| U.S. detections (CDC) | Detected in 25 states (as of Feb. 11) | Widely variable |
| Share in parts of Northern Europe | ~30% (Germany, Denmark, Netherlands) | Depends on season |
The table summarizes publicly reported points of comparison: lineage origin and mutation burden, observed geographic share in some European countries, and the number of U.S. states reporting detections by CDC surveillance as of Feb. 11. These figures reflect surveillance snapshots that can change quickly as sequencing and wastewater sampling continue.
Reactions & Quotes
Public-health and academic voices have been measured, emphasizing ongoing study rather than firm conclusions about severity or dominance.
“BA.3.2 is currently a minority strain, based on the most recent data available from CDC.”
Dr. Robert H. Hopkins, National Foundation for Infectious Diseases (medical director)
Hopkins’ comment underscores that, at the national level, BA.3.2 has not yet overtaken other lineages and is being tracked within broader surveillance systems.
“Early data would indicate that it is not more severe, or it doesn’t have any distinctive clinical presentations.”
Dr. William Schaffner, Vanderbilt University Medical Center
Schaffner highlights the distinction between laboratory signals and clinical outcomes, noting that, so far, clinicians have not observed new symptom patterns tied to BA.3.2.
“Home test kits will still work. Just make sure they aren’t expired.”
Dr. Donald Milton, University of Maryland (respiratory expert)
Milton’s practical guidance reassures the public that antigen tests target conserved viral components and remain useful for diagnosing infection when used correctly.
Unconfirmed
- Whether BA.3.2 will become the dominant strain in the United States remains unknown and depends on transmissibility and chance events.
- The precise degree to which BA.3.2 reduces vaccine effectiveness in real-world settings beyond laboratory neutralization assays is not yet established.
- Data linking BA.3.2 to increased clinical severity compared with recent Omicron sublineages are lacking and unproven.
Bottom Line
BA.3.2, nicknamed “cicada,” is a genetically distinct Omicron-lineage variant first seen in November 2024 that has reappeared in multiple regions and been detected across 25 U.S. states as of Feb. 11. Laboratory studies suggest it has mutations that may reduce antibody neutralization, but clinical severity and its capacity to outcompete other variants are not yet demonstrated.
For individuals, the practical guidance remains unchanged: stay up to date with recommended COVID-19 vaccines—especially if you are older or immunocompromised—use home tests when symptomatic, and follow public-health guidance. Agencies will continue genomic and epidemiologic surveillance, and vaccine strain selection bodies will consider BA.3.2 data as they plan future formulations.
Sources
- PBS NewsHour (news analysis)
- U.S. Centers for Disease Control and Prevention (official surveillance)
- World Health Organization (official updates and technical briefings)
- PolitiFact (original reporting/source attribution)